Levetiracetam Dosing and Therapeutic Monitoring in End‑Stage Renal Disease (ESRD)

Immediate Management of Supratherapeutic Levels

• In a patient with ESRD, a levetiracetam concentration of 63.3 µg/mL (≈ 38 % above the upper therapeutic limit of 46 µg/mL) warrants holding the next 1–2 doses before any dose reduction is instituted. The KDIGO 2024 guideline highlights the need for rapid action when levels exceed the therapeutic window. [1][2]

Therapeutic Drug Monitoring (TDM) Recommendations

• KDIGO 2024 advises that, for medications with narrow therapeutic windows in CKD, clinicians should obtain both pre‑dialysis and post‑dialysis levetiracetam levels, aim for trough concentrations of 12–46 µg/mL, and re‑measure 3–5 days after any dose change to account for the prolonged half‑life in ESRD. Ongoing monitoring for CNS adverse effects (e.g., somnolence, behavioral changes) is also recommended. [1][2]3

Guideline Society Emphasis on Prompt Dose Adjustment

• The KDIGO 2024 guidelines stress that medications with narrow therapeutic windows must be adjusted promptly in CKD patients to avoid toxicity or breakthrough seizures; delays in dose modification are discouraged. [1][2][3][4]

Assessment of Renal Function for Dosing Decisions

• In ESRD, serum creatinine does not reliably reflect renal clearance; creatinine clearance is essentially zero regardless of measured serum creatinine values, necessitating dosing based on dialysis status rather than creatinine‑based estimates. [1][2]